OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels

Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) to meet unmet patient needs [3] - The company collaborates with leading academic institutions and biopharmaceutical companies to create transformative medicines for serious diseases [3] Recent Developments - OSE Immunotherapeutics has launched its inaugural Newsletter aimed at individual shareholders and investors, marking the 10th anniversary of its listing on Euronext Paris [2] - The Newsletter will provide updates on company developments, insights into team efforts, and deeper discussions on topics typically covered in press releases [2] Communication Strategy - The Newsletter will be published regularly in both French and English and will be accessible in the "Investors" section of the OSE Immunotherapeutics website [2] - This initiative is intended to enhance communication with individual shareholders and express appreciation for their continued support [2]